578 related articles for article (PubMed ID: 10335908)
1. Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer.
Lecaillon JB; Kaiser G; Palmisano M; Morgan J; Della Cioppa G
Eur J Clin Pharmacol; 1999 Apr; 55(2):131-8. PubMed ID: 10335908
[TBL] [Abstract][Full Text] [Related]
2. Single-dose pharmacokinetics and safety pharmacodynamics of formoterol delivered by two different dry powder inhalers.
Petzold U; Kremer HJ; Nguyen DT; Munzel U; Dietrich H; Maus J
J Aerosol Med Pulm Drug Deliv; 2008 Sep; 21(3):309-19. PubMed ID: 18598160
[TBL] [Abstract][Full Text] [Related]
3. Comparable efficacy and tolerability of formoterol (Foradil) administered via a novel multi-dose dry powder inhaler (Certihaler) or the Aerolizer dry powder inhaler in patients with persistent asthma.
Dahl R; Creemers JP; Van Noord J; Sips A; Della Cioppa G; Thomson M; Andriano K; Kottakis J; Fashola T
Respiration; 2004; 71(2):126-33. PubMed ID: 15031566
[TBL] [Abstract][Full Text] [Related]
4. Formoterol delivered via a new multi-dose dry powder inhaler (Certihaler) is as effective and well tolerated as the formoterol dry powder inhaler (Aerolizer) in children with persistent asthma.
Chuchalin AG; Manjra AI; Rozinova NN; Skopková O; Cioppa GD; Till D; Kaiser G; Fashola T; Kottakis J
J Aerosol Med; 2005; 18(1):63-73. PubMed ID: 15741775
[TBL] [Abstract][Full Text] [Related]
5. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial.
Dalby C; Polanowski T; Larsson T; Borgström L; Edsbäcker S; Harrison TW
Respir Res; 2009 Oct; 10(1):104. PubMed ID: 19878590
[TBL] [Abstract][Full Text] [Related]
6. Nebulized formoterol fumarate: Dose selection and pharmacokinetics.
Gross NJ; Kerwin E; Levine B; Kim KT; Denis-Mize K; Hamzavi M; Carpenter M; Rinehart M
Pulm Pharmacol Ther; 2008 Oct; 21(5):818-23. PubMed ID: 18655841
[TBL] [Abstract][Full Text] [Related]
7. A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler.
Bensch G; Lapidus RJ; Levine BE; Lumry W; Yegen U; Kiselev P; Della Cioppa G
Ann Allergy Asthma Immunol; 2001 Jan; 86(1):19-27. PubMed ID: 11206232
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra-long-acting β₂-adrenoceptor agonist, with formoterol in patients with asthma.
Bjermer L; Rosenborg J; Bengtsson T; Lötvall J
Ther Adv Respir Dis; 2013 Oct; 7(5):264-71. PubMed ID: 23907810
[TBL] [Abstract][Full Text] [Related]
9. Comparative bioavailability of two hydrofluoroalkane formulations of formoterol fumarate both delivered by pressurised metered dose inhaler.
Po CJ; Chandran SS; Syed N; Naidu KR; Rathod M; Sule A; Lulla A; Purandare S
Arzneimittelforschung; 2010; 60(2):81-6. PubMed ID: 20329656
[TBL] [Abstract][Full Text] [Related]
10. A pharmacokinetic/pharmacodynamic study comparing arformoterol tartrate inhalation solution and racemic formoterol dry powder inhaler in subjects with chronic obstructive pulmonary disease.
Kharidia J; Fogarty CM; Laforce CF; Maier G; Hsu R; Dunnington KM; Curry L; Baumgartner RA; Hanrahan JP
Pulm Pharmacol Ther; 2008 Aug; 21(4):657-62. PubMed ID: 18501650
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and effects of formoterol fumarate in healthy human subjects after oral dosing.
van den Berg BT; Braat MC; van Boxtel CJ
Eur J Clin Pharmacol; 1998 Aug; 54(6):463-8. PubMed ID: 9776436
[TBL] [Abstract][Full Text] [Related]
12. Tolerability of high cumulative doses of the HFA modulite beclomethasone dipropionate/formoterol combination inhaler in asthmatic patients.
Singh D; Piccinno A; Borrill Z; Poli G; Acerbi D; Meuleners L; Woodcock A
Pulm Pharmacol Ther; 2008; 21(3):551-7. PubMed ID: 18321744
[TBL] [Abstract][Full Text] [Related]
13. The extrapulmonary effects of increasing doses of formoterol in patients with asthma.
Burgess C; Ayson M; Rajasingham S; Crane J; Della Cioppa G; Till MD
Eur J Clin Pharmacol; 1998 Apr; 54(2):141-7. PubMed ID: 9626918
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease.
Rosenkranz B; Rouzier R; Kruse M; Dobson C; Ayre G; Horowitz A; Fitoussi S
Respir Med; 2006 Apr; 100(4):666-72. PubMed ID: 16303295
[TBL] [Abstract][Full Text] [Related]
15. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects.
Guhan AR; Cooper S; Oborne J; Lewis S; Bennett J; Tattersfield AE
Thorax; 2000 Aug; 55(8):650-6. PubMed ID: 10899240
[TBL] [Abstract][Full Text] [Related]
16. Tolerability to high doses of formoterol and terbutaline via Turbuhaler for 3 days in stable asthmatic patients.
Tötterman KJ; Huhti L; Sutinen E; Backman R; Pietinalho A; Falck M; Larsson P; Selroos O
Eur Respir J; 1998 Sep; 12(3):573-9. PubMed ID: 9762782
[TBL] [Abstract][Full Text] [Related]
17. Cumulative high doses of inhaled formoterol have less systemic effects in asthmatic children 6-11 years-old than cumulative high doses of inhaled terbutaline.
Kaae R; Agertoft L; Pedersen S; Nordvall SL; Pedroletti C; Bengtsson T; Johannes-Hellberg I; Rosenborg J
Br J Clin Pharmacol; 2004 Oct; 58(4):411-8. PubMed ID: 15373934
[TBL] [Abstract][Full Text] [Related]
18. One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma.
Bensch G; Berger WE; Blokhin BM; Socolovsky AL; Thomson MH; Till MD; Castellsague J; Della Cioppa G;
Ann Allergy Asthma Immunol; 2002 Aug; 89(2):180-90. PubMed ID: 12197575
[TBL] [Abstract][Full Text] [Related]
19. Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics.
Rosenborg J; Bengtsson T; Larsson P; Blomgren A; Persson G; Lötvall J
Eur J Clin Pharmacol; 2000 Aug; 56(5):363-70. PubMed ID: 11009043
[TBL] [Abstract][Full Text] [Related]
20. Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study.
Houghton CM; Langley SJ; Singh SD; Holden J; Monici Preti AP; Acerbi D; Poli G; Woodcock A
Br J Clin Pharmacol; 2004 Oct; 58(4):359-66. PubMed ID: 15373928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
